X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Natco Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
ADCOCK INGRAM
Jun-14
NATCO PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,080368-   
Low Rs671265-   
Sales per share (Unadj.) Rs592.1109.3-  
Earnings per share (Unadj.) Rs188.4-27.6-  
Cash flow per share (Unadj.) Rs206.3-22.8-  
Dividends per share (Unadj.) Rs8.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs833.685.8-  
Shares outstanding (eoy) m36.90168.78-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.52.9 51.1%   
Avg P/E ratio x4.6-11.5 -40.5%  
P/CF ratio (eoy) x4.2-13.9 -30.6%  
Price / Book Value ratio x1.13.7 28.5%  
Dividend payout %4.40-   
Avg Mkt Cap Rs m32,31153,397 60.5%   
No. of employees `0004.84.3 112.5%   
Total wages/salary Rs m3,2563,351 97.2%   
Avg. sales/employee Rs Th4,522.54,298.8 105.2%   
Avg. wages/employee Rs Th674.0780.6 86.3%   
Avg. net profit/employee Rs Th1,439.0-1,083.2 -132.9%   
INCOME DATA
Net Sales Rs m21,84818,455 118.4%  
Other income Rs m404129 312.6%   
Total revenues Rs m22,25218,584 119.7%   
Gross profit Rs m9,284-3,198 -290.3%  
Depreciation Rs m662796 83.1%   
Interest Rs m154500 30.8%   
Profit before tax Rs m8,872-4,365 -203.2%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920273 703.9%   
Profit after tax Rs m6,952-4,650 -149.5%  
Gross profit margin %42.5-17.3 -245.2%  
Effective tax rate %21.6-6.2 -346.3%   
Net profit margin %31.8-25.2 -126.3%  
BALANCE SHEET DATA
Current assets Rs m21,30713,517 157.6%   
Current liabilities Rs m5,9207,605 77.8%   
Net working cap to sales %70.432.0 219.9%  
Current ratio x3.61.8 202.5%  
Inventory Days Days73111 66.0%  
Debtors Days Days107124 85.9%  
Net fixed assets Rs m14,9867,879 190.2%   
Share capital Rs m36986 430.7%   
"Free" reserves Rs m30,3530-   
Net worth Rs m30,76014,485 212.4%   
Long term debt Rs m05,090 0.0%   
Total assets Rs m37,15127,363 135.8%  
Interest coverage x58.6-7.7 -758.0%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.7 87.2%   
Return on assets %19.1-15.2 -126.1%  
Return on equity %22.6-32.1 -70.4%  
Return on capital %29.3-19.8 -148.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m7,3430-   
CASH FLOW
From Operations Rs m4,6361,575 294.3%  
From Investments Rs m-11,155-484 2,306.3%  
From Financial Activity Rs m6,5094,620 140.9%  
Net Cashflow Rs m-185,711 -0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.07 Rs / ZAR

Compare NATCO PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: PIRAMAL ENTERPRISES  GLENMARK PHARMA  FRESENIUS KABI ONCO.  JUBILANT LIFE SCIENCES  PLETHICO PHARMA  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 20, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS